CBX7 and cancer: These findings are in agreement with other studies in colon [30], bladder [31], pancreatic [32], breast [33], gastric [46], thyroid [47], liver and lung [34] cancers, in which the loss of CBX7 is correlated with a highly malignant phenotype and the retention of CBX7 expression with a longer survival of colon [30] and pancreatic cancer patients [32].